Gongwin Biopharm Holdings Co. Ltd.

6617 · TWO · Healthcare / Biotechnology

137.00TWD+9.00 (+7.03%)

Price History

Full chart

Market Stats

Previous Close128.00

Open128.50

Day Range127.50 – 137.50

52-Week Range58.30 – 149.00

Volume1.35M

Market Cap9.21B

P/E (TTM)0.00

Forward P/E0.00

EPS-1.34

Dividend Yield0.00%

Beta0.29

50-Day Avg114.86

200-Day Avg85.58

About

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment. Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Chonghan Wu Ph.D.
Employees0
HeadquartersNo. 80, Jianguo North Road, Taipei, Taiwan, 10491, Taiwan
Websitehttps://www.gongwinbiopharm.com

Leadership

Mr. Chonghan Wu Ph.D.Founder & Chairman · b. 1966
Mr. Mao-Yuan LinGM & Director · b. 1961
Chang En WangAssistant Manager of Marketing Division
Rocky ShihCo-Founder

Financials

Income Statement

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	1.14M	1.14M	18.91M	32.04M	36.45M
Growth (%)	-	0.00%	+1554.86%	+69.39%	+13.75%
Cost of Revenue	65.00K	77.00K	7.71M	23.36M	10.36M
Gross Profit	1.08M	1.07M	11.20M	8.68M	26.09M
Gross Margin	94.31%	93.26%	59.21%	27.09%	71.58%
Operating Expense	121.90M	261.75M	144.53M	164.83M	235.02M
Operating Income	-120.83M	-260.68M	-133.33M	-156.15M	-208.93M
Operating Margin	-10570.95%	-22806.74%	-704.87%	-487.35%	-573.26%
EBITDA	-	-275.56M	-80.66M	-75.97M	-103.99M
EBITDA Margin	-	-24108.66%	-426.43%	-237.10%	-285.32%
Net Income	-121.58M	-254.19M	-92.04M	-82.55M	-114.13M
Net Income Margin	-10637.01%	-22238.76%	-486.58%	-257.64%	-313.14%
R&D	83.05M	194.32M	52.65M	63.27M	119.47M
R&D as % of Total Revenue	7266.32%	17000.87%	278.35%	197.46%	327.81%
Interest Expense	1.18M	3.19M	7.19M	4.30M	5.16M
Interest Expense % of Total Revenue	103.24%	278.65%	38.01%	13.43%	14.16%

Balance Sheet

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	1.17B	1.62B	1.52B	3.38B	2.80B
Total Liabilities	184.43M	248.70M	203.53M	281.84M	279.20M
Total Equity	970.72M	1.39B	1.32B	3.11B	2.53B
Cash	454.12M	671.51M	273.59M	893.47M	968.90M

Cash Flow

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-95.51M	-232.20M	-110.80M	-87.41M	-135.75M
Capital Expenditure	54.00K	6.17M	1.13M	206.13M	2.46M
Free Cash Flow	-95.56M	-238.37M	-111.93M	-293.54M	-138.21M
FCF to OCF	100.06%	102.66%	101.02%	335.82%	101.81%

Key Statistics & Ratios

Market Cap9.21B

Enterprise Value15.68B

Trailing P/E0.00

Forward P/E0.00

Price / Sales408.43

Price / Book7.39

EPS-1.34

Book Value19.21

Revenue (TTM)42.22M

Gross Profit (TTM)26.64M

EBITDA-232.54M

Profit Margin0.00%

Operating Margin-484.51%

Return on Equity-7.36%

Return on Assets-5.65%

Shares Outstanding121.12M

Shares Float53.58M

Beta0.29

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%